The primary analysis of KATHERINE, a phase 3, open-label trial, showed that the risk of invasive breast cancer or death was 50% lower with adjuvant trastuzumab emtansine (T-DM1) than with ...

A subcutaneous formulation of Roche’s Perjeta and Herceptin breast cancer drugs works as well as an original intravenous (IV) version, a study has shown. Roche’s Genentech unit is developing a ...

Roche has had time to defend Herceptin against biosimilars, however. A patent-protected subcutaneous formulation of the drug was launched some years ago, and now represents 50% or more of the market.

Before that, the Swiss pharma owned part of the company and held marketing rights outside the US to Herceptin as well as other Genentech drugs. Typically, the volume of a subcutaneous injection is ...